ReviewInternational journal of molecular sciences2024
Unveiling the Secrets of
Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Comparative effectiveness of antimicrobial regimens for pneumonia caused by drug-resistant Acinetobacter baumannii: a network meta-analysis including cefiderocol and inhaled therapies.BMC infectious diseases · 2026Pooled it
- Data-driven Atlas ofFrontiers in cellular and infection microbiology · 2026Pooled it
- Therapeutic efficacy and mechanisms of Xuebijing inFrontiers in pharmacology · 2025Pooled it
- Review
- A monoclonal antibody targeting OXA23 restores carbapenem susceptibility in global epidemic carbapenem-resistantAntimicrobial agents and chemotherapy · 2026Article
- Virulence and Resistance Mechanisms in Multidrug-ResistantPathogens (Basel, Switzerland) · 2026Review
- Fosfomycin as an adjunctive agent against carbapenem-resistant Acinetobacter baumannii: an updated narrative review.Infection · 2026Review
- Eravacycline as a Novel Option for Treating Multidrug-Resistant Gram-Negative and Gram-Positive Bacterial Infections: A Narrative Review.Journal of clinical medicine · 2026Review
- Article
- Review
- Article
- High-Resolution Genomic Surveillance of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- The Silent Threat: Unveiling Pathogenicity and Antimicrobial Resistance in Nonfermenting Gram-Negative Bacilli.Cureus · 2026Review
- Membrane-Focused Strategies AgainstAntibiotics (Basel, Switzerland) · 2026Review
- Exploratory Insights on Epidemiology, Genomic Features and Pangenome Analysis of NDM-1-Positive Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Integrated wet lab and in silico discovery and characterization of bacteriophages with antibiotic synergy against multidrug resistant Acinetobacter baumannii.Scientific reports · 2026Article
- Sulbactam-Durlobactam in the Treatment of Bloodstream Infection Due to Carbapenem-ResistantJournal of clinical medicine · 2026Review
- Revisiting the Fight AgainstAntibiotics (Basel, Switzerland) · 2026Review
- Draft genome sequence of an Acinetobacter baumannii strain belonging to CC79 isolated from a reference hospital in Brazil.Molecular biology reports · 2026Article
- Quercetin as a promising HIS-C inhibitor and novel therapeutic against antibacterial drug-resistant Acinetobacter baumannii: in vitro and in silico insights.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.